NICKLAUS CHILDRENS HOSPITAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $6.4M
- Transactions
- 1,610
- Companies
- 40
- Average per transaction
- $4,002
Who reported the payments
| GW Research Limited | $638,989 |
| Pacira Pharmaceuticals Incorporated | $551,014 |
| Travere Therapeutics, Inc. | $512,425 |
| Pfizer | $419,647 |
| Jazz Pharmaceuticals Inc. | $415,799 |
| Novartis | $393,285 |
| Ultragenyx Pharmaceutical Inc. | $388,428 |
| UCB SA | $313,938 |
| Vertex | $210,284 |
| Zogenix Inc. | $173,731 |
| Neurelis, Inc. | $140,405 |
| Takeda Pharmaceuticals U.S.A., Inc. | $136,177 |
| Hoffmann-la Roche Limited | $121,285 |
| CSL Behring | $104,137 |
| Biomarin Pharmaceutical Inc. | $100,268 |
| Astellas Pharma Global Development | $97,061 |
| AbbVie | $94,140 |
| Incyte Corporation | $87,637 |
| W. L. Gore & Associates, Inc. | $84,555 |
| Eli Lilly | $83,976 |
| Stryker | $75,909 |
| Neuropace, Inc. | $75,215 |
| Amgen | $71,738 |
| Merit Medical Systems Inc | $69,521 |
| Johnson & Johnson | $66,818 |
| Eisai Inc. | $60,751 |
| Immedica Pharma US, Inc. | $52,360 |
| Astrazeneca UK Limited | $48,041 |
| Merck | $45,254 |
| H. Lundbeck A S | $43,197 |
| Bayer | $40,259 |
| Ipsen Biopharmaceuticals, Inc | $37,059 |
| Janssen Research & Development, LLC | $35,524 |
| Chiesi USA, Inc. | $32,275 |
| Astellas US Technologies | $31,899 |
| Swedish Orphan Biovitrum AB | $30,396 |
| Medical Device Business Services, Inc. | $30,000 |
| SK Life Science, Inc. | $26,807 |
| Genentech, Inc. | $26,295 |
| Modernatx, Inc. | $23,639 |